Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV) (Q30398001)

From Wikidata

Jump to navigation Jump to search

scientific article published on December 30, 2010

Language	Label	Description	Also known as
English	Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV)	scientific article published on December 30, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV) (English)

1 reference

10.1016/J.VACCINE.2010.12.037

https://api.crossref.org/works/10.1016/J.VACCINE.2010.12.037

21 November 2024

0 references

vector-borne disease

0 references

6

object named as

Reinhard Kurth

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Wolfgang Poller

4

object named as

Wolfgang Poller

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

author name string

Isaac Sipo

1

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Mathias Knauf

2

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Henry Fechner

3

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Oliver Planz

5

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Stephen Norley

7

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

language of work or name

0 references

publication date

30 December 2010

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0264410X10018104?httpAccept=text/xml

1 reference

10.1016/J.VACCINE.2010.12.037

https://api.crossref.org/works/10.1016/J.VACCINE.2010.12.037

21 November 2024

https://api.elsevier.com/content/article/PII:S0264410X10018104?httpAccept=text/plain

1 reference

10.1016/J.VACCINE.2010.12.037

https://api.crossref.org/works/10.1016/J.VACCINE.2010.12.037

21 November 2024

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

1690-1699

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Vaccination with hemagglutinin or neuraminidase DNA protects BALB/c mice against influenza virus infection in presence of maternal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

The cryptic life style of adeno-associated virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Long-term regulated expression of growth hormone in mice after intramuscular gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Identification of an epitope on the P and V proteins of simian virus 5 that distinguishes between two isolates with different biological characteristics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Differential internalization and nuclear uncoating of self-complementary adeno-associated virus pseudotype vectors as determinants of cardiac cell transduction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Identification of H‐2Kb Binding and Immunogenic Peptides from Human Papilloma Virus Tumour Antigens E6 and E7

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Early presence of ribonucleoprotein antigen on surface of influenza virus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Heterologous protection against influenza by injection of DNA encoding a viral protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Genetic fate of recombinant adeno-associated virus vector genomes in muscle

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Adeno-associated virus vectors in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

The state of the art of adeno-associated virus-based vectors in gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Swine-origin pandemic H1N1 influenza virus-like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Alternative live-attenuated influenza vaccines based on modifications in the polymerase genes protect against epidemic and pandemic flu.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

A candidate H1N1 pandemic influenza vaccine elicits protective immunity in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Protection against mouse and avian influenza A strains via vaccination with a combination of conserved proteins NP, M1 and NS1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Measuring the diaspora for virus-specific CD8+ T cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Cell-mediated protection in influenza infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Purified influenza virus nucleoprotein protects mice from lethal infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Pandemic influenza vaccines

1

1 reference

10.1016/J.VACCINE.2010.12.037

https://api.crossref.org/works/10.1016/J.VACCINE.2010.12.037

21 November 2024

rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice

14

1 reference

10.1016/J.VACCINE.2010.12.037

https://api.crossref.org/works/10.1016/J.VACCINE.2010.12.037

21 November 2024

Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice

51

1 reference

10.1016/J.VACCINE.2010.12.037

https://api.crossref.org/works/10.1016/J.VACCINE.2010.12.037

21 November 2024

Identifiers

10.1016/J.VACCINE.2010.12.037

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30398001&oldid=2277745793"